ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2014
Rotavirus vaccines in routine use.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 5 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Evidence of rotavirus vaccine impact in sub-Saharan Africa: Systematic review and meta-analysis.PloS one · 2020Pooled it
- Effectiveness of RotarixWellcome open research · 2020Pooled it
- Kawasaki Disease and the Use of the Rotavirus Vaccine in Children: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2019Pooled it
- Systematic review of the rotavirus infection burden in the WHO-EMRO region.Human vaccines & immunotherapeutics · 2019Pooled it
- 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Guideline
- Safety and immunogenicity of the Rotavac and Rotasiil rotavirus vaccines administered in an interchangeable dosing schedule among healthy Indian infants: a multicentre, open-label, randomised, controlled, phase 4, non-inferiority trial.The Lancet. Infectious diseases · 2022Trial
- Timing of Rotavirus Vaccine Doses and Severe Rotavirus Gastroenteritis Among Vaccinated Infants in Low- and Middle-income Countries.Epidemiology (Cambridge, Mass.) · 2018Trial
- Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa.AIDS (London, England) · 2017Trial
- Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules.Pediatrics · 2016Trial
- Long-Term Survival of Human Enteric Virus Surrogates (Murine Norovirus, Rhesus Rotavirus, and Porcine Sapovirus) in Bottled Drinking Water.Food and environmental virology · 2026Article
- Rotavirus mucosal immunology: insights and research priorities from an international convening in Liverpool, March 2024.NPJ vaccines · 2026Article
- Maternal-infant rotavirus-specific antibody kinetics to inform timing of vaccine boosting in Malawi: An observational study.PLoS medicine · 2025Observational
- Single domain antibodies from camelids in the treatment of microbial infections.Frontiers in immunology · 2024Review
- Anti-rotavirus antibody measurement in a rotavirus vaccine trial: Choice of vaccine antigen in immunoassays does matter.Human vaccines & immunotherapeutics · 2023Article
- The Influence of Introducing Free Vaccination againstVaccines · 2023Article
- Article
- Rotavirus and bacterial diarrhoea among children in Ile-Ife, Nigeria: Burden, risk factors and seasonality.PloS one · 2023Article
- Article
- Healthcare provider perspectives on delivering next generation rotavirus vaccines in five low-to-middle-income countries.PloS one · 2022Article
- Parenteral, non-live rotavirus vaccine: recent history and future perspective.Clinical and experimental vaccine research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Vaccines are now available to combat rotavirus, the most common cause of severe diarrhea among children worldwide. We review clinical trial data for available rotavirus vaccines and summarize postlicensure data on effectiveness, impact, and safety from countries routinely using these vaccines in national programs. In these countries, rotavirus vaccines have reduced all-cause diarrhea and rotavirus hospitalizations by 17%-55% and 49%-92%, respectively, and all-cause diarrhea deaths by 22%-50% in some settings. Indirect protection of children who are age-ineligible for rotavirus vaccine has also been observed in some high and upper middle income countries. Experience with routine use of rotavirus vaccines in lower middle income countries has been limited to date, but vaccine introductions in such countries have been increasing in recent years. The risk-benefit analysis of rotavirus vaccines is extremely favorable but other strategies to improve the effectiveness of the vaccine, particularly in lower middle income settings, should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.